Clinical outcomes in cancer patients with immune checkpoint inhibitor-induced arthritis treated with methotrexate: a retrospective longitudinal monocentric pilot study
Authors' conclusion
The use of MTX in ICI-induced arthritis showed promising results in reducing GC dosages and managing the inflammatory articular activity, with no major toxicities observed over one year.
Study context
- Population
- Adult cancer patients with ICI-induced arthritis in 2023 (median age 74.5 years)
- Participants
- 14 patients
- Outcome
- Articular (DAS28-CRP, every 3 months) and oncologic outcomes (RECIST 1.1)
- Follow-up
- One year
Methodological detailslongitudinal, monocentric, pilot
- Longitudinal
- Monocentric
- Pilot
Main finding
As reported in the abstract
Prednisone dosage, V4 vs V0
Prednisone dosage at V4
3.6 mg
Prednisone dosage at V0
8.4 mg
Observational data: associations, not effects.
Further findings
Cancer response at follow-up (RECIST 1.1)
- Complete response
- 50%
- Partial response
- 21.4%
- Stable disease
- 7.1%
- Progression
- 21.5%
Safety
- No major methotrexate (MTX)-related toxicities were noted
Original publication
Clinical outcomes in cancer patients with immune checkpoint inhibitor-induced arthritis treated with methotrexate: a retrospective longitudinal monocentric pilot study. Clin Exp Rheumatol. Published 1 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →